Renata Alves Silva, Isabela Rosier Olimpio Pereira, José Mendes Aldrighi, Mohamed H. Saleh, André Arpad Faludi, José Antonio Franchini Ramires, Marcelo Chiara Bertolami, Jose Eduardo M.R. Sousa, Y Nakamura, and Dulcinéia Saes Parra Abdalla
This double blind randomized placebo controlled study assessed the effects of atorvastatin, estradiol and norethisterone, isolated and in combination, on the lipid profile and on vascular reactivity, in post-menopausal women with hypercholesterolemia and arterial hypertension. Ninety-four women aged 50–65 were selected. All have received dietary counseling (4 weeks), placebo (4 weeks), and drug therapy (12 weeks): 17-β estradiol 2mg/day (E) ( n = 17); E + norethisterone acetate 1mg/day (P) ( n = 18); Atorvastatin 10mg/day (A) ( n = 20); E + A ( n = 21) and E + P + A ( n = 18). All treatment modalities have significantly reduced total cholesterol (TC) (E = 8.8%, E + P=10.1%, A=27.9%, A + E=29.4% and E + P + A=35.7%) and LDL-cholesterol (LDL-c) levels (E + P + A=46.6%, E + A=45.9%, A=40.2%, E=20.3%, and E + P=12.1%). As concerns HDL-cholesterol (HDL-c), Groups E and E + A had increases of 15.5% and 13.1%, respectively. The addition of a progesterone compound reduced its concentration (Group E + P=−9.1%, and Group E + P + A=−9.5%). By random, approximately half of the patients in each group were designated to the endothelial function evaluation (brachial artery ultrasound). We observed that in Group A ( n = 10), in Group E ( n = 10) and with the association (Group E + A) ( n = 7), there was a significant increase in the flow-mediated vasodilatation as compared to basal measurements. The addition of a progestin has annulled these benefits. Conclusions: Atorvastatin has promoted more beneficial effects on TC and LDL-c, whereas estradiol was responsible for an increase in HDL-c. The addition of a progesterone derivative abolished these benefits. Atorvastatin, estradiol or both together improved endothelial function, an effect suppressed by the addition of norethisterone.